ST3GAL1

CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 1 · Q11201 · ST3GAL1 on Sugi Atlas →

6,335 patent compounds predicted against ST3GAL1, 5,734 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL801929	0.79	2/20
SCHEMBL805327	0.63	2/20
SCHEMBL3698541	0.54	2/20
SCHEMBL2496466	0.52	2/20
SCHEMBL1310798	0.44	2/20
SCHEMBL2448736	0.43	2/20
Lithocholic Acid (SCHEMBL28449)	1.00	1/20
Lithocholic Acid (SCHEMBL28450)	1.00	1/20
Lithocholic Acid (SCHEMBL75701)	1.00	1/20
Isolithocholic Acid (SCHEMBL289049)	1.00	1/20
Lithocholic Acid (SCHEMBL1688740)	1.00	1/20
Lithocholic Acid (SCHEMBL2476803)	1.00	1/20
Lithocholic Acid (SCHEMBL3925326)	1.00	1/20
Lithocholic Acid (SCHEMBL3933390)	1.00	1/20
Lithocholic Acid (SCHEMBL3937888)	1.00	1/20
Lithocholic Acid (SCHEMBL3683819)	0.98	1/20
Lithocholic Acid (SCHEMBL3683820)	0.98	1/20
Lithocholic Acid (SCHEMBL233591)	0.92	1/20
Lithocholic Acid (SCHEMBL3618772)	0.92	1/20
Lithocholic Acid (SCHEMBL288628)	0.88	1/20

Clinical trials — most relevant to ST3GAL1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
A Study Evaluating Glycosphingolipid Clearance in Patients Treated With Agalsidase Alfa Who Switch to Agalsidase Beta	PHASE4	COMPLETED
A Study Comparing ATB200/AT2221 With Alglucosidase Alfa/Placebo in Adult Subjects With Late-onset Pompe Disease	PHASE3	COMPLETED
A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis	PHASE1/PHASE2	RECRUITING
An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Primary Focal Segmental Glomerulosclerosis	PHASE2	RECRUITING
Multi-Center Study of ManNAc for GNE Myopathy	PHASE2	ACTIVE_NOT_RECRUITING
An Open Label Phase 2 Study of ManNAc in Subjects With GNE Myopathy	PHASE2	COMPLETED
A Study Evaluating the Safety and Pharmacokinetics of Aldurazyme® (Laronidase) in MPS I Patients Less Than 5 Years Old	PHASE2	COMPLETED
A Study of Monosialic Gangliosides to Prevent Albumin-bound Paclitaxel Neurotoxicity	PHASE2	COMPLETED
Open-Label Study of Efficacy and Safety of Recombinant Human N-acetylgalactosamine 4-sulfatase in Patients With MPS VI	PHASE2	COMPLETED
A Phase 1 Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ManNAc in Subjects With Primary Podocyte Diseases	PHASE1	COMPLETED
Autologous Stem Cell Transplantation of Cells Engineered to Express Alpha-Galactosidase A in Patients With Fabry Disease	PHASE1	COMPLETED
Biomarker for Mucolipidosis Disorder Type I, II, III, IV (BioML)	nan	WITHDRAWN
A Retrospective Study to Identify New Omics Biomarkers of Chronic/Persistent Low Back Pain	nan	COMPLETED
The Natural History of Alpha-Mannosidosis	nan	COMPLETED
Sialic Acid Supplementation in N-Acetylneuraminic Acid Synthase (NANS) Deficiency	nan	COMPLETED
Glycosylation in Patients With Galactosaemia	nan	COMPLETED
Biomarker for Gangliosidosis: BioGM1/BioGM2 (BioGM1/GM2)	nan	WITHDRAWN
A Natural History Study of Patients With GNE Myopathy and GNE-Related Diseases	nan	COMPLETED
Evaluation of Gastrointestinal Symptoms Following Chilean Native Beans Consumption	nan	UNKNOWN
Evaluation of Blood Brain Barrier Integrity and Structural Abnormalities in MPS IIIB Patients Using Multimodal Magnetic Resonance Imaging	nan	COMPLETED
The Natural History Study of Patients With Sanfilippo Disease(s) (MPS3)	nan	UNKNOWN
Evaluation of Blood and Cardiac Protein O-GlcNAcylation Levels in Cardiac Surgery in Children	nan	RECRUITING
Respiratory Cathepsins, Proteases Inhibitors and Glycosaminoglycans (GAG) in Mucopolysaccharidosis	nan	COMPLETED
Registry Gangliosidoses	nan	UNKNOWN
BMN 110 US Expanded Access Program	nan	APPROVED_FOR_MARKETING
Biomarker for Farber Disease (BioFarber)	nan	WITHDRAWN
Inflammatory Pathways and Cardiac Growth Factors Associated With Fabry Disease Cardiomyopathy	nan	UNKNOWN
Fibrosis, Inflammation, Oxygenation of Renal Tissue In FabrY Disease	nan	RECRUITING
The Natural History of Sialidosis Type I	nan	RECRUITING
Mucin Glycosylating Enzymes in Head and Neck Cancers	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a ST3GAL1 binder may also engage these)

Protein	Name	Similarity
Q6KB59	—	1.000	Q6KB59 →
Q02745	—	1.000	Q02745 →
P61130	—	1.000	P61130 →
Q08E15	—	0.999	Q08E15 →
P54751	—	0.997	P54751 →
Q11206	—	0.997	Q11206 →
Q11200	—	0.997	Q11200 →
Q16842	—	0.996	Q16842 →
Q91Y74	—	0.995	Q91Y74 →
Q92184	—	0.995	Q92184 →
O15466	—	0.995	O15466 →
Q8NDV1	—	0.995	Q8NDV1 →
Q02734	—	0.994	Q02734 →
P61131	—	0.994	P61131 →
Q6ZXC8	—	0.993	Q6ZXC8 →
Q11205	—	0.993	Q11205 →
Q68G12	—	0.993	Q68G12 →
Q9Y274	—	0.993	Q9Y274 →
Q11204	—	0.993	Q11204 →
Q92183	—	0.992	Q92183 →
P70277	—	0.992	P70277 →
Q64690	—	0.992	Q64690 →
Q92187	—	0.992	Q92187 →
P61645	—	0.992	P61645 →
O35696	—	0.992	O35696 →
Q64689	—	0.991	Q64689 →
Q70D51	—	0.991	Q70D51 →
Q969X2	—	0.991	Q969X2 →
Q6KB58	—	0.991	Q6KB58 →
Q07977	—	0.991	Q07977 →